Statements (66)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:virus
|
| gptkbp:advocacy |
aim to improve access to care
|
| gptkbp:alcohol_avoidance |
alcohol consumption should be avoided
|
| gptkbp:associated_with |
chronic liver disease
extrahepatic manifestations |
| gptkbp:caused_by |
HCV infection
|
| gptkbp:chronic_fatigue_syndrome |
may be associated with chronic fatigue
|
| gptkbp:chronicity |
can lead to chronic infection
|
| gptkbp:clinical_trial |
ongoing for new treatments
disproportionately affects marginalized communities |
| gptkbp:community_impact |
affects quality of life
|
| gptkbp:complication |
liver cancer
liver cirrhosis |
| gptkbp:demographics |
more common in men
higher prevalence in certain ethnic groups |
| gptkbp:diagnosis |
blood test
often asymptomatic in early stages |
| gptkbp:diseases |
can last for decades
HIV co-infection common |
| gptkbp:duration |
8 to 12 weeks
|
| gptkbp:economic_impact |
costly to treat
|
| gptkbp:fibrosis_assessment |
Fibro Scan used for non-invasive assessment
|
| gptkbp:financial_support |
support groups available
|
| gptkbp:genotype |
multiple genotypes exist
|
| gptkbp:global_health_issue |
recognized by WHO
|
| gptkbp:guideline_updates |
based on emerging evidence
|
| gptkbp:healthcare_provider_role |
important in management and support
|
| https://www.w3.org/2000/01/rdf-schema#label |
Chronic Hepatitis C
|
| gptkbp:influenced_by |
diet and exercise recommended
|
| gptkbp:is_a_resource_for |
available for affected individuals
|
| gptkbp:is_vulnerable_to |
no vaccine available
|
| gptkbp:liver_biopsy |
used to assess liver damage
|
| gptkbp:liver_function_test |
elevated liver enzymes
|
| gptkbp:liver_transplant |
may be necessary in severe cases
|
| gptkbp:mental_health_impact |
can lead to depression
|
| gptkbp:patient_education |
important for treatment adherence
|
| gptkbp:post_treatment_monitoring |
required to check for recurrence
|
| gptkbp:prevalence |
approximately 71 million people worldwide
|
| gptkbp:prevention |
screening of blood products
safe injection practices |
| gptkbp:propagation_method |
blood-to-blood contact
|
| gptkbp:provides_guidance_on |
updated regularly by health organizations
access varies by region |
| gptkbp:public_awareness |
aim to reduce stigma
increased through campaigns and education. |
| gptkbp:public_health_strategy |
elimination goals set by WHO
|
| gptkbp:research_focus |
new antiviral therapies
|
| gptkbp:risk_factor |
intravenous drug use
blood transfusion before 1992 |
| gptkbp:screening_frequency |
annually for high-risk individuals
|
| gptkbp:screening_tests |
HCV RNA test used for confirmation
|
| gptkbp:screenings |
recommended for high-risk populations
|
| gptkbp:side_effect |
gptkb:anemia
fatigue headache nausea |
| gptkbp:support |
may require ongoing monitoring
|
| gptkbp:symptoms |
fatigue
abdominal pain jaundice |
| gptkbp:treatment |
gptkb:immunotherapy
sustained virologic response improved with early treatment high with direct-acting antivirals |
| gptkbp:bfsParent |
gptkb:Mavyret
|
| gptkbp:bfsLayer |
6
|